文献速递胸部肿瘤

肿瘤及肿瘤相关巨噬细胞PD-L1表达与肺腺癌辅助化疗获益相关

Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma.
PubMed 文献 · J Thorac Oncol · 2021-10-08

该研究基于475例II-III期初治肺腺癌患者组织芯片,用多重免疫荧光检测PD-L1、TAMs等免疫标志物,发现TAMs或肿瘤细胞高表达PD-L1者接受辅助化疗生存获益更佳,低/无表达者无获益。

要点

  • TAMs或肿瘤细胞PD-L1高表达者辅助化疗生存获益更佳。
  • TAMs和肿瘤细胞均高表达且髓系-淋巴系比值高者获益更显著。
  • TAMs或肿瘤细胞PD-L1低/无表达者辅助化疗无生存获益。

核心结论

  • TAMs或肿瘤细胞PD-L1表达与肺腺癌辅助化疗生存获益相关,低/无表达者无获益。

研究设计与样本

  • 回顾性分析475例II-III期初治肺腺癌患者肿瘤及瘤周间质组织芯片,多重免疫荧光检测免疫标志物,Cox模型校正病理分期。

主要发现

  • TAMs高PD-L1表达者辅助化疗生存获益改善(HR=1.79,95%CI:1.12-2.85)。
  • 肿瘤细胞高PD-L1表达者辅助化疗生存获益改善(HR=3.02,95%CI:1.69-5.40)。
  • TAMs高PD-L1且髓系-淋巴系比值高者辅助化疗获益显著(HR=3.87,95%CI:1.79-8.37)。
  • TAMs和肿瘤细胞均高PD-L1且髓系-淋巴系比值高者获益显著(HR=2.19,95%CI:1.02-4.71)。
  • TAMs高PD-L1且间质MDSC比值高者获益显著(HR=2.53,95%CI:1.29-4.96);TAMs和肿瘤细胞均高PD-L1且间质MDSC比值高者获益显著(HR=3.21,95%CI:1.23-8.35)。

临床怎么用

  • 可依据TAMs和肿瘤细胞PD-L1表达及髓系-淋巴系比值、间质MDSC比值筛选辅助化疗潜在获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with stage II to III lung adenocarcinomas are treated with adjuvant chemotherapy (ACT) to target the premetastatic niche that persists after curative-intent resection. We hypothesized that the premetastatic niche is a scion of resected lung tumor microenvironment and that analysis of tumor microenvironment can stratify survival benefit from ACT. METHODS: Using tumor and tumoral stroma from 475 treatment-naive patients with stage II to III lung adenocarcinomas, we constructed a tissue microarray and performed multiplex immunofluorescent staining for immune markers (programmed death-ligand 1 [PD-L1], tumor-associated macrophages [TAMs], and myeloid-derived suppressor cells) and derived myeloid-lymphoid ratio. The association between immune markers and survival was evaluated using Cox models adjusted for pathologic stage. RESULTS: Patients with high PD-L1 expression on TAMs or tumor cells in resected tumors had improved survival with ACT (TAMs: hazard ratio [HR] = 1.79, 95% confidence interval [CI]: 1.12-2.85; tumor cells: HR = 3.02, 95% CI: 1.69-5.40). Among patients with high PD-L1 expression on TAMs alone or TAMs and tumor cells, ACT survival benefit is pronounced with high myeloid-lymphoid ratio (TAMs: HR = 3.87, 95% CI: 1.79-8.37; TAMs and tumor cells: HR = 2.19, 95% CI: 1.02-4.71) or with high stromal myeloid-derived suppressor cell ratio (TAMs: HR = 2.53, 95% CI: 1.29-4.96; TAMs and tumor cells: HR = 3.21, 95% CI: 1.23-8.35). Patients with low or no PD-L1 expression on TAMs or tumor cells had no survival benefit from ACT. CONCLUSIONS: Our observation that PD-L1 expression on TAMs or tumor cells is associated with improved survival with ACT provides rationale for prospective investigation and developing chemoimmunotherapy strategies for patients with lung adenocarcinoma.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Gross DJ, Chintala NK, Vaghjiani RG, et al. Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. J Thorac Oncol. 2021. PMID: 34634452. doi:10.1016/j.jtho.2021.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。